Skip to content
★ Sign in to follow
Indo Us Biotech Limited logo

Indo Us Biotech Limited Stock: price and insider trades · India

IN·Mcap ₹1.5BHealth Care

Indo Us Biotech Limited: what insiders have been doing

This page follows insider dealings at Indo Us Biotech Limited as filed with SEBI (PIT + SAST), a company from the Health Care sector. Over the twelve months to 8 November 2026, 6 filings were filed, from 1 insider.

The flow runs one way only: 6 sales worth €461k, from 1 insider, and no purchase. At €120k, the sale published on 11 February 2026 by Indo US Agriseeds Limited is the largest of the period.

Typically, a trade is published a median of 2 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Compared with its exchange (1,986 companies, median 4 filings), a count of 6 filings is above the norm. Looking back to 2026, when coverage begins, insiders filed no purchases and 6 sales.

For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.

Insider Decl.
6
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€461,442
6 ops. · all time

Who traded when

BuySale
Indo US Agriseeds Limited6 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 11,668 of 26,914 companies
55.0
score / 100
Value
50
Quality
60
FCF yld-10%
Earn yld9.2%
EV/EBITDA10.6x
ROE15%
Gross mgn26%
Net mgn12%
Debt/EBITDA2.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹75.58
Analyst consensus
·
Income statement
Revenue₹1.1B
Gross profit₹283.6M26% margin
EBITDA₹169.6M15% margin
Net income₹131.2M10.2% margin
Valuation
PER (trailing)13.3x
P/Book1.6x
Beta0.27
Balance sheet & cash
Market cap₹1.5B
Total debt₹370.4M
Free Cash Flow-₹149.9M
Debt / Equity40%
Profitability & ownership
ROE15.3%
ROA8.7%
% insiders75.5%
% institutions0.0%
Last declaration on 5 March 2026
Declarations6 total
  • ▼
    Related company / holdingExecutives
    7M INR6SEBI
    50,000 shares@ ₹141.0014.1% of flowEquity SharesSEBI:deacd69ce9ba201eb132074b40607f9a3bffe2cb
  • ▼
    Related company / holdingExecutives
    7M INR6SEBI
    50,000 shares@ ₹140.0014.1% of flowEquity SharesSEBI:5fd28c5956aac1503c83418ff056cb5f4c45c9e7
  • ▼
    Related company / holdingExecutives
    10M INR7SEBI
    75,000 shares@ ₹130.0019.6% of flowEquity SharesSEBI:d82985efdc3abffbe0f0ce58635f939365ecf7b8
  • ▼
    Related company / holdingExecutives
    13M INR8SEBI
    100,000 shares@ ₹130.0026.0% of flowEquity SharesSEBI:9ee9a3b573e1def4c88eae98696ef08de6f771cf
  • ▼
    Related company / holdingExecutives
    284,130 INR5SEBI
    2,255 shares@ ₹126.000.6% of flowEquity SharesSEBI:7cfc7de19db752d0234d49114b5e6fa821d0770b
  • ▼
    Related company / holdingExecutives
    13M INR8SEBI
    100,000 shares@ ₹126.0025.6% of flowEquity SharesSEBI:7689dea37bb6133365bf4c56f326fc0027c5feb1

6 of 6 declarations

About Indo Us Biotech Limited

Indo Us Biotech Limited is a company specializing in the healthcare and pharmaceutical sector. It is listed on the XBOM.